Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

Merck, which previously predicted 2024 sales of between ... patents & legal, executive appointments, commercial strategy and ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Healthcare & Pharmaceuticalscategory Merck signs up to $3.3 bln cancer drug deal with China-based LaNova 1:38 PM UTC · Updated ago Technologycategory China's JD.com struggles to shake off consumption ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

He also held roles as Merck’s Vice President, Corporate Information Technology and business-line CIO for its Global Commercial Organization and various corporate functions. While at Merck, George led ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

The drug is being developed by the Chinese biotech Abbisko Therapeutics Co. Merck KGaA holds commercial license for Pimicotinib in Chinese mainland, Hong Kong, Macau, and Taiwan, it said.